Acurx Pharmaceuticals Inc Ordinary Shares ACXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Trading Information
- Previous Close Price
- $1.03
- Day Range
- $0.98–1.06
- 52-Week Range
- $0.95–7.54
- Bid/Ask
- $1.00 / $1.05
- Shares Outstanding
- 6.06M
- Market Cap
- $5.39M
- Volume/Avg
- 158,936 / 124,742
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acurxpharma.com
Valuation
Metric | ACXP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ACXP |
|---|---|
Quick Ratio | 3.80 |
Current Ratio | 3.88 |
Interest Coverage | — |
Quick Ratio
ACXP
Profitability
Metric | ACXP |
|---|---|
Return on Assets (Normalized) | −76.46% |
Return on Equity (Normalized) | −111.98% |
Return on Invested Capital (Normalized) | −114.93% |
Return on Assets
ACXP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&&?Zt> | LOCK|WS#qD | $139B | |||
| Moderna Inc MRNA | LOCK|N$D#D> | LOCK|<Z | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&%#lX@! | LOCK|y?T! | $99B | |||
| argenx SE ADR ARGX | LOCK|KxX!?Bw | LOCK|lh | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$>$$%T | LOCK|w> | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&^YXq?^H | LOCK|^T#D | $31B | |||
| Incyte Corp INCY | LOCK|$FDP&#j | LOCK|Q& | $25B | |||
| BioNTech SE ADR BNTX | LOCK|y>$KGQw | LOCK|cGB | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|pp%&n>X | LOCK|@<??C | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|RbZxd< | LOCK|?M | $16B |
United States